Evaluating the Clinical & Practical Advantages for Community Adoption of Allogeneic NK Cell Therapies
2:00 pm - Thursday 3rd December 2026
- Demonstrating clinical and translational data, including PK-PD relationships, cytokine profiles and biomarker insights, to validate the advantages of allo-NK approaches for improved efficacy and safety outcomes
- Comparing allo-NK therapies against alternative modalities to clarify mechanistic benefits and identify where they offer differentiated clinical value across autoimmune indications
- Addressing manufacturing and point-of-care delivery strategies to enable scalable, cost-effective deployment while maintaining product consistency and accessibility
